The UK will donate 100 million surplus coronavirus vaccine doses to the world within the next year, the Prime Minister has announced
The UK will donate at least 100 million surplus coronavirus vaccine doses within the next year, including 5 million beginning in the coming weeks
Donation is in addition to UK work to support Oxford-AstraZeneca’s contribution to fighting COVID and our financial backing to COVAX
G7 leaders are expected to agree to provide 1 billion doses via dose sharing and financing to end the pandemic in 2022
The UK will donate 100 million surplus coronavirus vaccine doses to the world within the next year, the Prime Minister has announced today (11 June 2021).
The pledge comes ahead of the G7 Summit, which begins in Cornwall today. Last week the Prime Minister asked fellow G7 leaders to help vaccinate the entire world by the end of next year.
At the Summit world leaders are expected to announce they will provide at least 1 billion coronavirus vaccine doses to the world through dose sharing and financing and set out a plan to expand vaccine manufacturing in order to achieve that goal.
The UK will donate 5 million doses by the end of September, beginning in the coming weeks, primarily for use in the world’s poorest countries.
The Prime Minister has also committed to donating a further 95 million doses within the next year, including 25 million more by the end of 2021. 80% of the 100m doses will go to COVAX and the remainder will be shared bilaterally with countries in need.
By sharing 5 million doses in the coming weeks the UK will meet an immediate demand for vaccines for the countries worst affected by coronavirus without delaying completion of our initial domestic vaccination programme.
By vaccinating more people around the world not only will we help bring an end to the global coronavirus pandemic, we will reduce the risk to people in the UK. This includes significantly reducing the threat posed by vaccine-resistant variants emerging in areas with large-scale outbreaks.
The UK helped to establish COVAX last year and is its fourth-biggest donor, pledging £548 million to the scheme. COVAX has so far provided 81 million doses to 129 of the world’s poorest countries. 96% of these were the Oxford-AstraZeneca vaccine, the development of which was funded by the UK.
With the support of the UK Government, Oxford-AstraZeneca are distributing their vaccines on a not for profit basis the world. Thanks to this commitment, half a billion people have received a dose of the Oxford-AstraZeneca vaccine so far.
The Prime Minister said: “Since the start of this pandemic the UK has led the way in efforts to protect humanity against this deadly disease. Over a year ago we funded the development of the Oxford-AstraZeneca vaccine on the basis it would be distributed at cost to the world.
“This unprecedented model, which puts people squarely above profit, means over half a billion doses have been administered in 160 countries so far.
“As a result of the success of the UK’s vaccine programme we are now in a position to share some of our surplus doses with those who need them. In doing so we will take a massive step towards beating this pandemic for good.
“At the G7 Summit I hope my fellow leaders will make similar pledges so that, together, we can vaccinate the world by the end of next year and build back better from coronavirus.”
At the G7 leaders will also discuss how to expand the supply of vaccines internationally, with the Prime Minister asking the group to encourage pharmaceutical companies to adopt the Oxford-AstraZeneca model of providing vaccines of cost for the duration of the pandemic.
Pfizer, Moderna and Johnson & Johnson have already pledged to share 1.3 billion doses on a non-profit basis with developing countries.
Leaders are expected to discuss additional ways to support countries experiencing acute coronavirus emergencies and put in place mechanisms to prevent future pandemics. This follows on from commitments made at the virtual meeting of G7 leaders earlier this year.
The cost of donating the UK’s surpluses will be classified as ODA. This will be in addition to the £10bn already committed in aid this year.
The doses the UK has announced it will donate today will be drawn from the UK’s expected excess supply. The 100 million figure has been calculated based on the total needed to vaccinate the UK population, factoring in the possibility of future vaccine-resistant strains being detected and potential disruptions to our supply.
Later this year the UK will also host the UN climate change conference, COP26. Today the UK is also announcing that in order to enable more representatives to attend safely we will work to provide vaccines to those accredited delegations who would be unable to get them otherwise. We are exploring with the UN and partners how we can work together to deliver this offer.
This will mean that those countries most affected by climate change are better able to participate fully in discussions about creating a greener future for the planet.
A hygiene campaign launched by the Government and Unilever to tackle Covid-19 has now reached one billion people.
The world’s largest hygiene campaign aimed at tackling the spread of Covid-19 has reached one billion people.
The UK Government and Unilever partnered to provide soap, sanitiser and surface disinfectants to developing countries, where there is little or no sanitation.
This comes as the UK-backed COVAX scheme reaches deliveries of vaccines to 100 countries and territories.
One billion people in developing countries have now been reached with advice, hygiene products and access to handwashing facilities in a campaign launched between the UK government and British business Unilever to reduce the spread of Covid-19.
Working through the UN, charities and other partners, the campaign has:
Trained 140,000 staff, including community health workers and teachers, to deliver hygiene skills, including deep cleaning of public buildings and effective handwashing.
Installed over 500,000 handwashing stations around the world, including in Bangladesh, as well as health care facilities in Iraq.
Run information campaigns across TV, radio and social media in 37 countries to increase understanding of the benefits of handwashing with soap regularly and disinfecting surfaces to prevent the spread of Covid-19. These campaigns have also reached refugees living in some of the world’s worst humanitarian crises, such as South Sudan and Cox’s Bazar in Bangladesh.
Delivered 75 million Unilever hygiene products, more than three times the original target, to 60 countries, covering South America, Europe, Africa, Asia, South East Asia and the Middle East. These have been donated by Unilever’s leading hygiene brands, including Lifebuoy and Domestos.
The UK has been leading the international response to the Covid-19 pandemic, helping to develop and distribute vaccines support the global economy and bolster health systems around the world.
As one of the largest donors to the COVAX AMC, the UK is also helping stop the spread of the disease through global vaccinations. The scheme has reached 100 countries so far.
The Prime Minister has also confirmed the UK will share the majority of any future surplus coronavirus vaccines from our supply with the COVAX procurement pool to support developing countries.
Foreign, Commonwealth & Development Office Minister Wendy Morton said: “This global hand washing campaign has saved lives and protected some of the most vulnerable communities around the world against Covid-19 and other diseases.
“No one is safe until we are all safe. That is why the UK has also provided £548 million for COVAX to deliver more than one billion vaccines around the world, as well as lobbying international partners to increase their funding.”
As well as the UK Government and Unilever, the campaign, funded by UK aid and Unilever, is also supported by experts from the London School of Hygiene & Tropical Medicine and 21 partners including UNICEF and the United Nations High Commissioner for Refugees who are helping governments around the world on their own Covid-19 responses.
Charities and international organisations have developed new tools to communicate how Covid-19 is spread. Population Services International developed a WhatsApp chatbot to send new training to health workers while remaining socially-distanced and safe.
Rebecca Marmot, Chief Sustainability Officer at Unilever, said: “Our business has a century-long history of promoting hygiene through our brands, but this unprecedented crisis called for an unprecedented response.
“Public-private partnership has been critical, allowing us to leverage the influence, expertise and networks of both government and business, and our strong network of NGO and UN partners, at home and overseas. We’re pleased to work together with partners to implement initiatives to address the pandemic at scale.”
Robert Dreibelbis, from the London School of Hygiene & Tropical Medicine, said: “Handwashing and hygiene are among the most effective ways to help prevent the spread of many diseases.
“The COVID-19 crisis has shown the important role that hygiene plays in health. Our hope is that this recognition of the vital role of hygiene continues at scale as a key part of COVID-19 recovery.”
At the halfway point in the World Health Organization and Director-General Tedros Adhanom Ghebreyesus’ 100-day challenge, a movement of people and organizations is now uniting together under the banner of vaccine equity.
WHO welcomes the new commitments made by France, Germany, the United Kingdom of Great Britain and Northern Ireland and the United States of America to COVAX and equitable allocation of vaccines.
Backed by 190 countries and economies, COVAX is the global mechanism best positioned to deliver vaccines to the world and end the COVID-19 pandemic.
“There is a growing movement behind vaccine equity and I welcome that world leaders are stepping up to the challenge by making new commitments to effectively end this pandemic by sharing doses and increasing funds to COVAX,” said Dr Tedros, Director-General of the World Health Organization.
“This can’t be business as usual and there is an urgent need for countries to share doses and technology, scale up manufacturing and ensure that there is a sustainable supply of vaccines so that everyone, everywhere can receive a vaccine.”
Close to 7000 people and hundreds of organizations have already signed on to a vaccine equity declaration that directly calls on governments and manufacturers to speed up regulatory processes, boost manufacturing by sharing know-how and technology, and ensure that doses are shared equitably.
There is a specific call to start with all health and care workers, who have been on the frontlines of this pandemic for more than a year.
Heads of state and sports stars like Romain Grosjean; international agencies including UNICEF, UN Development Programme, UN Women and the World Food Programme; sporting organizations like the International Olympic Committee, World Rugby and FIFA; networks focused on faith, gender and youth, and civil society groups like the Elders, Global Health Council, Nursing Now, Pandemic Action Network, UHC2030 and Women in Global Health,*– these and many more have signed on to the broad based movement, which recognizes the moral, economic and global security imperative of equitable vaccine distribution.
Dr Keith C Rowley, Prime Minister of Trinidad and Tobago, and Chairman of the Caribbean Community and Common Market (CARICOM) said, “Today, thankfully we are at that place where we now have tested and proven vaccines.
“A brightening light is shining on our way towards a more successful response to the still marauding virus.”
The movement for vaccine equity is growing, and to prevent virus variants from undermining our health technologies and hampering an already sluggish global economic recovery, it is critical that leaders continue to step up to ensure that we end this pandemic as quickly as possible. Individuals and organizations everywhere are encouraged to join in this crucial effort.
COVAX: World unites to ensure vaccines will be available to all … but USA and China say NO
64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days
These self-financing economies, which include 29 from ‘Team Europe’ participating as part of an agreement with the European Commission, join 92 lower income economies eligible for financial support through the Gavi COVAX Advance Market Commitment
This means a total of 156 economies, representing nearly two-thirds of the global population, are now committed to or eligible to receive vaccines through the Facility Click here for the list of economies
64 higher income economies have joined the COVAX Facility, a global initiative that brings together governments and manufacturers to ensure eventual COVID-19 vaccines reach those in greatest need, whoever they are and wherever they live.
These 64 economies include commitments from 35 economies as well as the European Commission which will procure doses on behalf of 27 EU member states plus Norway and Iceland.
By pooling financial and scientific resources, these participating economies will be able to insure themselves against the failure of any individual vaccine candidate and secure successful vaccines in a cost-effective, targeted way.
The 64 members of the Facility will be joined by 92 low- and middle-income economies eligible for support for the procurement of vaccines through the Gavi COVAX Advance Market Commitment (AMC), a financing instrument aimed at supporting the procurement of vaccines for these countries.
This means that 156 economies, representing roughly 64% of the global population in total, are now either committed to or eligible for the COVAX Facility, with more to follow.
With the Commitment Agreements secured, the COVAX Facility will now start signing formal agreements with vaccine manufacturers and developers, which are partners in the COVAX effort, to secure the doses needed to end the acute phase of the pandemic by the end of 2021. This is in addition to an ongoing effort to raise funding for both R&D and for the procurement of vaccines for lower-income countries via the Gavi COVAX AMC.
“COVAX is now in business: governments from every continent have chosen to work together, not only to secure vaccines for their own populations, but also to help ensure that vaccines are available to the most vulnerable everywhere,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, which is coordinating the COVAX Facility.
“With the commitments we’re announcing today for the COVAX Facility, as well as the historic partnership we are forging with industry, we now stand a far better chance of ending the acute phase of this pandemic once safe, effective vaccines become available.”
The COVAX Facility is part of COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO) – working in partnership with developed and developing country vaccine manufacturers, UNICEF, the World Bank, Civil Society Organisations and others.
The allocation of vaccines, once licensed and approved, will be guided by an Allocation Framework released today by WHO following the principle of fair and equitable access, ensuring no participating economy will be left behind.
Policies determining the prioritization of vaccine rollout within economies will be guided by recommendations from the WHO Strategic Advisory Group of Experts on Immunization (SAGE), which has recently released a Values Framework laying the groundwork for subsequent guidance on target populations and policies on vaccine use.
“COVID-19 is an unprecedented global crisis that demands an unprecedented global response,” said WHO Director-General, Dr Tedros Adhanom Ghebreyesus. “Vaccine nationalism will only perpetuate the disease and prolong the global recovery.
“Working together through the COVAX Facility is not charity, it’s in every country’s own best interests to control the pandemic and accelerate the global economic recovery.”
The commitment of fully self-financing economies will now unlock vital funding and the security of demand needed to scale up manufacturing and secure the doses needed for the Facility. CEPI is leading COVAX vaccine research and development work, which aims to develop at least three safe and effective vaccines which can be made available to economies participating in the COVAX Facility. Nine candidate vaccines are currently being supported by CEPI; eight of which are currently in clinical trials.
“This is a landmark moment in the history of public health with the international community coming together to tackle this pandemic. The global spread of COVID-19 means that it is only through equitable and simultaneous access to new lifesaving COVID-19 vaccines that we can hope to end this pandemic”, said Dr Richard Hatchett, CEO of CEPI.
“Countries coming together in this way shows a unity of purpose and resolve to end the acute phase of this pandemic, and we must now work closely with vaccine manufacturers—who play an integral part in the global response—to put in place the agreements needed to fulfil COVAX’s core aim: to have two billion vaccine doses available by the end of 2021. Today, we have taken a great leap towards that goal, for the benefit of all.”
The success of COVAX hinges not only on economies signing up to the COVAX Facility and commitments from vaccine manufacturers, but also filling key funding gaps for both COVAX research and development (R&D) work and the Gavi COVAX AMC to support participation of lower income economies in the COVAX Facility.
Governments, vaccine manufacturers (in addition to their own R&D), organisations and individuals have committed US$ 1.4 billion towards vaccine R&D so far, but a further US$ 700-800 million is urgently needed to continue to move the portfolio forward in addition to US$ 300 million to fund WHO’s SOLIDARITY trial.
The Gavi COVAX AMC has raised around US$ 700 million from sovereign donors as well as philanthropy and the private sector, against an initial target of US$ 2 billion in seed funding needed by the end of 2020. Funding the Gavi COVAX AMC will be critical to ensuring ability to pay is not a barrier to accessing COVID-19 vaccines, a situation which would leave the majority of the world unprotected, with the pandemic and its impact continuing unabated.
The Commitment Agreements also commit higher income governments to provide an upfront payment to reserve doses by 9 October 2020. These funds will be used to accelerate the scale-up of vaccine manufacturing to secure two billion doses of vaccine, enough to vaccinate one billion people assuming the vaccine requires a two-dose regimen.
As well as procuring doses for participating economies, the COVAX Facility will also maintain a buffer of doses for emergency and humanitarian use.
Participating country comments
“COVID-19 poses serious health concerns to people everywhere, and that’s why Canada is committed to working with partners around the world to end the pandemic,” said the Rt. Hon. Justin Trudeau, Prime Minister of Canada.
“Equitable, timely, and affordable access to a safe and effective COVID vaccine will be critical to help protect people’s health. Canada supports the objectives and principles of the COVAX Facility as the only global pooled procurement mechanism for countries to collaborate on this monumental undertaking. Our country is a part of this important global response.”
“New Zealand’s commitment to the COVAX Facility supports access to vaccines against COVID-19 for other countries too,” said Rt Hon Jacinda Ardern, Prime Minister of New Zealand.
“COVAX and the idea of equal access to a COVID-19 vaccine, regardless of ability to pay, is not just a moral imperative, it is the only practical solution to this pandemic. Protecting everyone is the only way we can return our world – our trade, tourism, travel, business – to normal,” said the Honourable Dr Edwin G. Dikoloti, Minister of Health and Wellness for Botswana. “We urge those countries who have not yet signed up to do so. Let us work together to protect each other.”
“Immunisation saves lives. Investing in immunisation infrastructure helps strengthen health systems. We have seen this time and again through our work with Gavi and Alliance partners,” said Dr Lia Tadesse, Minister of Health for Ethiopia.
“By being a part of the COVAX Facility and the AMC we can continue this work and protect our citizens – and the world – against the impact of COVID-19.”
“With COVAX, the world is joining forces and proving that together, we are stronger – and together, we can defeat this pandemic,” said Ekaterine Tikaradze, Minister of Health for Georgia.
“Georgia will be joining the COVAX Facility to give our citizens the best chance at having access to safe vaccines. By doing this, we also make sure health care workers and other high risk persons all over the world have access to these life-saving tools, helping to bring the pandemic under control – and we can all recover and rebuild.”
“Joining the COVAX Facility was not a difficult decision – not only will this give Kuwaiti citizens access to COVID-19 vaccines as they become available, it will also mean our friends and partners outside our borders also get access,” said His Excellency Sheikh Dr Basel Humoud Al-Sabah, Minister of Health of the State of Kuwait.
“We need a global solution to this global pandemic: we believe COVAX is that solution.”
“We believe international cooperation – a global effort – is key,” said Dag-Inge Ulstein, Minister of International Development for Norway. “We must continue to work for equitable access to vaccines, tests and treatments.
“To defeat the coronavirus pandemic, well-off countries need to act swiftly and boldly to make vaccines and treatments available to those who cannot afford to pay themselves. With the commitments to the COVAX facility we are heading in the right direction.”
“This is a hugely important initiative, which could offer us a path out of the acute phase of this pandemic and a return to normality,” said His Excellency Dr Ahmed Mohammed Obaid Al Saidi, Minister of Health of the Sultanate of Oman.
“I would urge every country that has not yet done so to sign up, for all our sakes. It is far better for us to work together than apart.”
Partner comments:
“The history of vaccines will be defined by our response to COVID-19; the COVAX facility is at the epicenter of this response. Industry is at the forefront in vaccines development and manufacturing leading to supplies of several billion doses within the next few years”, said Mr. Sai D. Prasad, President of the Developing Countries Vaccine Manufacturers’ Network (DCVMN).
“The COVAX facility will have a major impact on lives, livelihoods and accelerate the return to normalcy for countries. The DCVMN is fully engaged with its partners to enhance its mission of global public health and to leave no one behind.”
“It is very encouraging to see so many countries move from talk to full commitment,” said Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers (IFPMA).
“The Facility can only work, and equitable access can only be achieved, if there is solidarity between rich and poorer countries. Today vaccine makers who have the unique skills and expertise to scale up manufacturing to levels never seen before, stand ready, together, to take up the challenge of providing two billion doses of yet unknown COVID-19 vaccines.
“This is no mean feat, as it requires doubling existing capacity in record time. Today, marks a significant step forward, and is a historic mark of solidarity which has the power to bring the acute phase of this pandemic to an end; and we are proud to be part of this unique endeavour to leave no one behind.”
“Uniting our efforts through COVAX must guarantee fair allocation and equitable delivery of the COVID-19 vaccine to those who need it most, and not just those who can afford it,” said Jagan Chapagain, Secretary-General of the International Federation of Red Cross and Red Crescent Societies.
“We all have a moral and public health imperative to protect the poor in rural communities as the affluent in cities, the old in care homes as the young in refugee camps. The power of our humanity and the success of COVAX will be measured by how we collectively protect the most vulnerable among us.”
“Global cooperation must be the cornerstone of our global response to COVID-19,” said Kevin Watkins, Chief Executive of Save the Children. “The COVAX Facility has the potential to help ensure universal and equitable access to future COVID vaccines.
“For this to happen, we need to ensure people in low- and middle-income countries get their fair share and can access the vaccines they need to help overcome the biggest public health and child rights crisis of our generation.”
“Seeing such unity in the face of the COVID-19 crisis gives us confidence that, together, we can ensure the equitable delivery of COVID vaccines globally,” said Henrietta Fore, UNICEF Executive Director.
“With our globe-spanning supply chain and on-the-ground presence across 190 countries, UNICEF is proud to support this historic effort.”
